Drug intelligence / Profile preview

anti-EGFRvIII CAR T cells + pembrolizumab

Development stage: Discontinued
Lead developer: University of Pennsylvania
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

A combination therapy consisting of chimeric antigen receptor (CAR) T cells targeting epidermal growth factor receptor variant III (EGFRvIII) and pembrolizumab, a PD-1 inhibitor. This investigational treatment was designed to target EGFRvIII-positive glioblastoma, based on the rationale that CAR T-cell therapy targeting EGFRvIII produces upregulation of PD-L1 in the tumor microenvironment, which might be counteracted by PD-1 inhibition.

Targets

PDCD1 (Programmed cell death protein 1 receptor)EGFRvIII (Epidermal growth factor receptor variant III)

Beyond the preview

Go deeper on anti-EGFRvIII CAR T cells + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-EGFRvIII CAR T cells + pembrolizumab.

Explore the full profile